PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsBendamustine
Bendamustine
Belrapzo, Bendamustine, Bendeka, Treanda, Vivimusta (bendamustine) is a small molecule pharmaceutical. Bendamustine was first approved as Treanda on 2008-03-20. It is used to treat lymphoid leukemia and non-hodgkin lymphoma in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
hemic and lymphatic diseasesD006425
immune system diseasesD007154
Trade Name
FDA
EMA
Belrapzo, Bendamustine, Bendeka, Treanda, Vivimusta (discontinued: Bendamustine, Treanda)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Bendamustine hydrochloride
Tradename
Company
Number
Date
Products
BENDAMUSTINE HYDROCHLORIDEApotexN-215033 RX2022-12-07
1 products, RLD, RS
VIVIMUSTAAzurityN-212209 RX2022-12-07
1 products, RLD, RS
BENDAMUSTINE HYDROCHLORIDEBaxterN-216078 RX2022-12-15
1 products, RLD, RS
TREANDACephalonN-022249 RX2008-03-20
2 products, RLD, RS
BELRAPZOEagle PharmaceuticalsN-205580 RX2018-05-15
1 products, RLD, RS
BENDEKAEagle PharmaceuticalsN-208194 RX2015-12-07
1 products, RLD, RS
Show 2 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
belrapzoNew Drug Application2024-09-23
bendamustineANDA2023-06-05
bendamustine hydrochlorideNew Drug Application2025-02-10
bendekaNew Drug Application2024-01-19
treandaNew Drug Application2022-10-27
vivimustaNew Drug Application2024-02-27
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
non-hodgkin lymphoma—D008228C85.9
lymphoid leukemia—D007945C91
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Bendamustine Hydrochloride, Vivimusta, Slayback Pharma Llc
118447842042-07-29DP
Bendamustine Hydrochloride, Bendeka, Eagle Pharms
90000212033-03-15U-1542
90349082033-03-15U-1542
91445682033-03-15U-1542
95728872033-03-15U-1971, U-1972
95793842033-03-15U-1971, U-1972
95973972033-03-15U-1971, U-1972
95973982033-03-15U-1971
95973992033-03-15U-1971, U-1972
100523852033-03-15U-1971, U-1972
Bendamustine Hydrochloride, Belrapzo, Eagle Pharms
86097072031-08-11DPU-1542, U-1971, U-1972
92658312031-01-28DP
95727962031-01-28DPU-1971, U-1972
95727972031-01-28U-1971, U-1972
100105332031-01-28DP
111034832031-01-28DPU-1971, U-1972
118447832031-01-28U-1542, U-1971, U-1972
118722142031-01-28DP
87912702026-01-12DPU-1542, U-1790, U-1971, U-1972
Bendamustine Hydrochloride, Treanda, Cephalon
84361902030-10-26DP
83440062029-09-23DPU-1402
84455242029-03-26DS, DPU-1402
86692792029-03-26DPU-1402
88838362029-03-26DPU-1402
95339552029-03-26DPU-1949, U-1952
86098632026-01-12DP
88957562026-01-12DP
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01A: Alkylating agents
— L01AA: Nitrogen mustard analogues
— L01AA09: Bendamustine
HCPCS
Code
Description
J9033
Injection, bendamustine hcl (treanda), 1 mg
J9034
Injection, bendamustine hcl (bendeka), 1 mg
J9036
Injection, bendamustine hydrochloride, (belrapzo/bendamustine), 1 mg
Clinical
Clinical Trials
422 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LymphomaD008223—C85.93122——17
Non-hodgkin lymphomaD008228—C85.9162——9
Mantle-cell lymphomaD020522———11——2
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LeukemiaD007938—C9535———7
Lymphoid leukemiaD007945—C9135———7
B-cell chronic lymphocytic leukemiaD015451—C91.124———6
Multiple myelomaD009101—C90.034———5
Plasma cell neoplasmsD054219——34———5
B-cell lymphomaD016393———4———4
Large b-cell lymphoma diffuseD016403—C83.3—3———3
Follicular lymphomaD008224—C82—2———2
Hodgkin diseaseD006689—C81—1———1
Immunoglobulin light-chain amyloidosisD000075363———1———1
Show 10 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369—C802————2
Brain neoplasmsD001932EFO_0003833C711————1
Neoplasm metastasisD009362EFO_0009708—1————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameBendamustine
INNbendamustine
Description
Bendamustine is a member of benzimidazoles.
Classification
Small molecule
Drug classantineoplastics (chloroethylamine derivatives)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21
Identifiers
PDB—
CAS-ID16506-27-7
RxCUI—
ChEMBL IDCHEMBL487253
ChEBI ID—
PubChem CID65628
DrugBankDB06769
UNII ID9266D9P3PQ (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Belrapzo – Eagle Pharmaceuticals
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Bendeka – Eagle Pharmaceuticals
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Treanda – Cephalon
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 7,692 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
24,010 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use